Dual COX-2/15-LOX inhibitors: A new avenue in the prevention of cancer.
15-LOX
Anticancer
COX-2
Enzyme inhibitors
Structure-activity relationship
Journal
European journal of medicinal chemistry
ISSN: 1768-3254
Titre abrégé: Eur J Med Chem
Pays: France
ID NLM: 0420510
Informations de publication
Date de publication:
05 Dec 2023
05 Dec 2023
Historique:
received:
27
08
2023
revised:
07
10
2023
accepted:
09
10
2023
medline:
3
11
2023
pubmed:
21
10
2023
entrez:
20
10
2023
Statut:
ppublish
Résumé
Dual cyclooxygenase 2/15-lipoxygenase inhibitors constitute a valuable alternative to classical non-steroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 (cyclooxygenase-2) inhibitors for the treatment of inflammatory diseases, as well as preventing the cancer. Indeed, these latter present diverse side effects, which are reduced or absent in dual-acting agents. In this review, COX-2 and 15-LOX (15-lipoxygenase) pathways are first described in order to highlight the therapeutic interest of designing such compounds. Various structural families of dual inhibitors are illustrated. This study discloses various structural families of dual 15-LOX/COX-2 inhibitors, thus pave the way to design potentially-active anticancer agents with balanced dual inhibition of these enzymes.
Identifiants
pubmed: 37862815
pii: S0223-5234(23)00833-4
doi: 10.1016/j.ejmech.2023.115866
pii:
doi:
Substances chimiques
Cyclooxygenase 2 Inhibitors
0
Cyclooxygenase 2
EC 1.14.99.1
Arachidonate 15-Lipoxygenase
EC 1.13.11.33
Anti-Inflammatory Agents, Non-Steroidal
0
Lipoxygenase Inhibitors
0
Arachidonate 5-Lipoxygenase
EC 1.13.11.34
Cyclooxygenase 1
EC 1.14.99.1
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
115866Informations de copyright
Copyright © 2023 Elsevier Masson SAS. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.